These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 25130853

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [Abstract] [Full Text] [Related]

  • 23. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
    Fang X, Xu S, Zhang Y, Xu J, Huang Z, Liu W, Wang S, Yen K, Zhang W.
    Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612
    [Abstract] [Full Text] [Related]

  • 24. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
    Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G.
    Leuk Res; 2023 Apr; 127():107044. PubMed ID: 36801700
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
    Zhang A, Wang S, Ren Q, Wang Y, Jiang Z.
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e183-e194. PubMed ID: 36471477
    [Abstract] [Full Text] [Related]

  • 29. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C, Tzankov A.
    Pathobiology; 2024 Oct; 91(1):55-75. PubMed ID: 37232015
    [Abstract] [Full Text] [Related]

  • 30. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.
    Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J.
    Blood Cancer J; 2017 Nov 27; 7(12):633. PubMed ID: 29176559
    [No Abstract] [Full Text] [Related]

  • 31. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.
    Blood; 2009 Jul 02; 114(1):144-7. PubMed ID: 19420352
    [Abstract] [Full Text] [Related]

  • 32. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata KC, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine RL, Abdel-Wahab O, Kitamura T.
    J Clin Invest; 2013 Nov 02; 123(11):4627-40. PubMed ID: 24216483
    [Abstract] [Full Text] [Related]

  • 33. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S.
    Cancer Res; 2010 Jan 15; 70(2):447-52. PubMed ID: 20068184
    [Abstract] [Full Text] [Related]

  • 34. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S.
    Leukemia; 2013 Sep 15; 27(9):1852-60. PubMed ID: 23628959
    [Abstract] [Full Text] [Related]

  • 35. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY, Huang CF, Lin TL, Wu JH, Wang PN, Dunn P, Kuo MC, Tang TC.
    Clin Cancer Res; 2005 Mar 01; 11(5):1821-6. PubMed ID: 15756005
    [Abstract] [Full Text] [Related]

  • 36. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Ronaghy A, Yang RK, Khoury JD, Kanagal-Shamanna R.
    Curr Hematol Malig Rep; 2020 Jun 01; 15(3):194-202. PubMed ID: 32382988
    [Abstract] [Full Text] [Related]

  • 37. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ, Pan LJ, Qin TJ, Xu ZF, Li B, Wang HJ, Sun Q, Jia YJ, Li CW, Cai WY, Gao QY, Jiao M, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2023 May 14; 44(5):373-379. PubMed ID: 37550186
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
    Hsu YC, Chiu YC, Lin CC, Kuo YY, Hou HA, Tzeng YS, Kao CJ, Chuang PH, Tseng MH, Hsiao TH, Chou WC, Tien HF.
    J Hematol Oncol; 2017 Jul 11; 10(1):139. PubMed ID: 28697759
    [Abstract] [Full Text] [Related]

  • 40. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Yang L, Wei X, Gong Y.
    Cancer Med; 2024 Jan 11; 13(1):e6871. PubMed ID: 38146893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.